Trial Profile

A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients With Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixazomib (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
Indications Mantle-cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

05 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Aug 2024.
05 May 2023 Planned primary completion date changed from 26 Aug 2022 to 15 Aug 2023.
26 Oct 2021 Planned primary completion date changed from 14 Sep 2021 to 26 Aug 2022.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com